trial
as of 2026-07-01Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
NCTId NCT07379827
at a glance
Phase — · Recruiting
Enrollment 1,500 (estimated)
Sponsored by Bristol-Myers
Primary completion 2028-06-20
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Recruiting
Enrollment
1,500 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2026-02-26
Primary completion
2028-06-20
Eligibility
ALL · 18 Years
Interventions & indications
Indications
Sponsors
Bristol-MyersLead Sponsor
Sites
52 total
Bryant, United StatesAnaheim, United StatesAnaheim, United StatesChino, United StatesLa Palma, United StatesOceanside, United StatesStanford, United StatesBonita Springs, United StatesHialeah, United StatesHomestead, United StatesKendall, United StatesMiami, United States
Facts & assertions
4 sourced
Enrollment
1,500
Phase
NA
Primary Completion Date
2028-06-20
Status
RECRUITING
relationships
The graph out of here
drug
lead_sponsor
company
indication
indication
indication